The management of gastrointestinal symptoms in Parkinson’s disease

References

• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico–pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55(3), 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms: identification and management. Parkinsonism Relat. Disord.13(Suppl. 3), S450–S456 (2007).
   PubMed Web of Science ®Google Scholar
• Muangpaisan W, Mathews A, Hori H, Seidel D. A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J. Med. Assoc. Thai.94(6), 749–755 (2011).
   PubMedGoogle Scholar
• Shulman LM. Gender differences in Parkinson’s disease. Gend. Med.4(1), 8–18 (2007).
   PubMed Web of Science ®Google Scholar
• Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov. Disord.26(6), 1042–1048 (2011).
   PubMed Web of Science ®Google Scholar
• Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson’s disease. J. Neurol. Sci.262(1–2), 37–44 (2007).
   PubMed Web of Science ®Google Scholar
• Khusnutdinova E, Gilyazova I, Ruiz-Pesini E et al. A mitochondrial etiology of neurodegenerative diseases: evidence from Parkinson’s disease. Ann. NY Acad. Sci.1147, 1–20 (2008).
   PubMedGoogle Scholar
• Dickson DW, Fujishiro H, Orr C et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord.15(Suppl. 3), S1–S5 (2009).
   PubMedGoogle Scholar
• Gárdián G, Vécsei L. Medical treatment of Parkinson’s disease: today and the future. Int. J. Clin. Pharmacol. Ther.48(10), 633–642 (2010).
   PubMed Web of Science ®Google Scholar
• Kyle G. The physical, social and emotional effects of bowel dysfunction in Parkinson’s disease. Nurs. Times106(33), 20–22 (2010).
   PubMedGoogle Scholar
• Stacy M, Bowron A, Guttman M et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord.20(6), 726–733 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Prieto-Jurcynska C, Naidu Y et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov. Disord.25(6), 697–701 (2010).
   Google Scholar
• Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov. Disord.23(8), 1065–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Dickson DW, Braak H, Duda JE et al. Neuropathological assessment of PD: refining the diagnostic criteria. Lancet Neurol.8(12), 1150–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson’s disease. Gastroenterology87(4), 848–856 (1984).
   PubMed Web of Science ®Google Scholar
• Singaram C, Ashraf W, Gaumnitz EA et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet346(8979), 861–864 (1995).
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Walter GC, Wilder SL et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience153(3), 733–750 (2008).
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol.79(6), 581–583 (1990).
   PubMed Web of Science ®Google Scholar
• Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of PD. Exp. Neurol.218(1), 154–161 (2009).
   PubMedGoogle Scholar
• Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces PD gastrointestinal neuropathology. Neurobiol. Dis.36(1), 96–102 (2009).
   PubMed Web of Science ®Google Scholar
• Blandini F, Balestra B, Levandis G et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of PD. Neurosci. Lett.467(3), 203–207 (2009).
   PubMed Web of Science ®Google Scholar
• Kuo YM, Li Z, Jiao Y et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet.19(9), 1633–1650 (2010).
   PubMed Web of Science ®Google Scholar
• Tian YM, Chen X, Luo DZ et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson’s disease. Neuroscience153(3), 634–644 (2008).
   PubMedGoogle Scholar
• Chaumette T, Lebouvier T, Aubert P et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil.21(2), 215–222 (2009).
   PubMed Web of Science ®Google Scholar
• Anderson G, Noorian AR, Taylor G et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp. Neurol.207(1), 4–12 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol.33(6), 599–614 (2007).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol.2(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Natale G, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Parkinson’s disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol. Motil.20(7), 741–749 (2008).
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J. Neurol. Sci.289(1–2), 69–73 (2010).
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of PD: meta-analysis of randomized controlled trials. Drug Saf.33(2), 147–161 (2010).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, White LR et al. Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol.250(Suppl. 3), III30–III39 (2003).
   PubMed Web of Science ®Google Scholar
• Savica R, Carlin JM, Grossardt BR et al. Medical records documentation of constipation preceding Parkinson disease: a case–control study. Neurology73(21), 1752–1758 (2009).
   PubMed Web of Science ®Google Scholar
• Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat. Disord.13(Suppl.), S2–S7 (2007).
   Google Scholar
• Marras C, Schuele B, Munhoz RP et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology77(4), 325–333 (2011).
   PubMed Web of Science ®Google Scholar
• Krygowska-Wajs A, Cheshire WP Jr, Wszolek ZK et al. Evaluation of gastric emptying in familial and sporadic Parkinson disease. Parkinsonism Relat. Disord.15(9), 692–696 (2009).
   PubMedGoogle Scholar
• Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in PD: a systematic review. J. Neurol.256(9), 1391–1396 (2009).
   PubMed Web of Science ®Google Scholar
• Miller N, Allcock L, Hildreth AJ, Jones D, Noble E, Burn DJ. Swallowing problems in Parkinson disease: frequency and clinical correlates. J. Neurol. Neurosurg. Psychiatry80(9), 1047–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in PD. Mov. Disord.6(2), 151–156 (1991).
   PubMed Web of Science ®Google Scholar
• Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson’s disease: a pilot study. Mov. Disord.21(8), 1270–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson’s disease. Acta Neurol. Scand.117(1), 60–64 (2008).
   PubMed Web of Science ®Google Scholar
• Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson’s disease. J. Neurol. Sci.276(1–2), 79–83 (2009).
   PubMedGoogle Scholar
• Amantadine. In: American Hospital Formulary Service – Drug Information 2005. McEvoy GK (Ed.). American Society of Health-System Pharmacists, Bethesda, MD, USA, 592 (2005).
   Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov. Disord.25(15), 2493–2500 (2010).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR et al. on behalf of the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), scale presentation and clinimetric testing results. Mov. Disord.23(15), 2129–2170 (2008).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov. Disord.21(7), 916–923 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov. Disord.22(13), 1901–1911 (2007).
   PubMed Web of Science ®Google Scholar
• Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov. Disord.19(11), 1306–1312 (2004).
   PubMed Web of Science ®Google Scholar
• Perez Lloret S, Pirán Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhea in patients with PD. Mov. Disord.22(1), 107–111 (2007).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Bricker DE, Kramer AE et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development. Dysphagia15(3), 115–121 (2000).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Bricker DE, Robbins J, Kramer AE, Rosenbek JC, Chignell KA. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling. Dysphagia15(3), 122–133 (2000).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Robbins J, Lomax K et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia17(2), 97–114 (2002).
   PubMed Web of Science ®Google Scholar
• Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis. Colon Rectum39(6), 681–685 (1996).
   PubMed Web of Science ®Google Scholar
• Miller N, Allcock L, Hildreth AJ et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J. Neurol. Neurosurg. Psychiatry80(9), 1047–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Lebouvier T, Neunlist M, Bruley des Varannes S et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One5(9), e12728 (2010).
   PubMed Web of Science ®Google Scholar
• South AR, Somers SM, Jog MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Am. Acad. Neurol.74, 1198–1202 (2010).
   PubMedGoogle Scholar
• van der Burg JJ, Didden R, Jongerius PH, Rotteveel JJ. A descriptive analysis of studies on behavioural treatment of drooling (1970–2005). Dev. Med. Child Neurol.49(5), 390–394 (2007).
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Koopmann M et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology74(15), 1203–1207 (2010).
   PubMed Web of Science ®Google Scholar
• Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov. Disord.17(6), 1318–1320 (2002).
   PubMed Web of Science ®Google Scholar
• Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov. Disord.22(15), 2268–2273 (2007).
   PubMed Web of Science ®Google Scholar
• Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. Br. J. Clin. Pharmacol.63(1), 128–129 (2007).
   PubMedGoogle Scholar
• Kushnir M, Eilam A, Heldman E. Modafinil reduces drooling in Parkinson’s disease. Mov. Disord.21(Suppl. 13), S598–S599 (2006).
   Google Scholar
• Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology61(9), 1279–1278 (2003).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology62(1), 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov. Disord.22(16), 2430–2435 (2007).
   PubMed Web of Science ®Google Scholar
• Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.101, 48–57 (2006).
   PubMed Web of Science ®Google Scholar
• Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson’s disease patients? J. Clin. Pharm. Ther.34(6), 673–676 (2009).
   PubMedGoogle Scholar
• Baijens LW, Speyer R. Effects of therapy for dysphagia in PD: systematic review. Dysphagia24(1), 91–102 (2009).
   PubMed Web of Science ®Google Scholar
• Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. N. Engl. J. Med.346(15), 1174–1175 (2002).
   PubMed Web of Science ®Google Scholar
• Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov. Disord.11(1), 53–58 (1996).
   PubMed Web of Science ®Google Scholar
• White GN, O’Rourke F, Ong BS, Cordato DJ, Chan DK. Dysphagia: causes, assessment, treatment, and management. Geriatrics63(5), 15–20 (2008).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in PD. Expert Opin. Drug Metab. Toxicol.4(2), 193–203 (2008).
   PubMed Web of Science ®Google Scholar
• Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson’s disease. Mov. Disord.24(13), 1881–1892 (2009).
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez-Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am. J. Health Syst. Pharm.65(5), 414–419 (2008).
   PubMed Web of Science ®Google Scholar
• Friedenberg FK, Parkman HP. Delayed gastric emptying: whom to test, how to test, and what to do. Curr. Treat. Options Gastroenterol.9(4), 295–304 (2006).
   PubMedGoogle Scholar
• Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson’s disease patients with motor fluctuations: a systematic review. Mov. Disord.25(13), 2021–2034 (2010).
   PubMed Web of Science ®Google Scholar
• Pierantozzi M, Pietroiusti A, Brusa L et al.Helicobacter pylori eradication and L-DOPA absorption in patients with PD and motor fluctuations. Neurology66(12), 1824–1829 (2006).
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov. Disord.12(6), 946–951 (1997).
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov. Disord.22(9), 1239–1244 (2007).
   PubMed Web of Science ®Google Scholar
• Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment. Pharmacol. Ther.11(6), 1059–1066 (1997).
   PubMed Web of Science ®Google Scholar
• Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson’s disease. J. Rehabil. Med.41(13), 1085–1089 (2009).
   PubMed Web of Science ®Google Scholar
• Simón MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl. Psychophysiol. Biofeedback34(4), 273–277 (2009).
   PubMed Web of Science ®Google Scholar
• Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am. J. Gastroenterol.105(4), 890–896 (2010).
   PubMed Web of Science ®Google Scholar
• Ron Y, Avni Y, Lukovetski A et al. Botulinum toxin type-A in therapy of patients with anismus. Dis. Colon Rectum44(12), 1821–1826 (2001).
   PubMed Web of Science ®Google Scholar
• Krogh K, Christensen P. Neurogenic colorectal and pelvic floor dysfunction. Best Pract. Res. Clin. Gastroenterol.23(4), 531–543 (2009).
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann. Neurol.33(5), 490–493 (1993).
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in Parkinson’s disease. Mov. Disord.25(Suppl. 1), S98–S103 (2010).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Badiali D, Vacca L et al. Anorectal function in multiple system atrophy and Parkinson’s disease. Mov. Disord.15(1), 71–76 (2000).
   PubMedGoogle Scholar
• Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology125(5), 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Michelsen HB, Thompson-Fawcett M, Lundby L, Krogh K, Laurberg S, Buntzen S. Six years of experience with sacral nerve stimulation for fecal incontinence. Dis. Colon Rectum53(4), 414–421 (2010).
   PubMedGoogle Scholar
• Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev. Gastroenterol. Disord.8(1), 15–20 (2008).
   PubMedGoogle Scholar
• Salat-Foix D, Andrwes CN, Meddings J, Suchowersky O. Gastrointestinal symptoms in Parkinson disease – clinical aspects and management. Can. J. Neurol. Sci.38, 557–564 (2011).
   PubMed Web of Science ®Google Scholar